Skip to content

Uncategorized

NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic

    April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE / April 21, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), announced today it has advanced its strategy toRead More »NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic

    NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic

      April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE / April 19, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused onRead More »NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic

      NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows

        April 11, 2021 8:00am EDT Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada Oakville, Ontario – April 12, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drugRead More »NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows

        NeonMind Unveils Initial Treatment Offering at Specialty Mental Health Clinic in Mississauga

          March 23, 2021 8:00am EDT To Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic Licensing OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug developmentRead More »NeonMind Unveils Initial Treatment Offering at Specialty Mental Health Clinic in Mississauga

          NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal Subjects

            March 23, 2021 8:00am EDT Data Further Validates Psilocybin as a Drug Candidate for Obesity and Supports Development of NeonMind’s Drug Programs NEO-001 and NEO-002 OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug developmentRead More »NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal Subjects

            NeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss

              March 22, 2021 8:00am EDT OAKVILLE, ON / ACCESSWIRE / March 22, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced todayRead More »NeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss

              NeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate Developments

                March 10, 2021 8:00am EDT – Completed concrete milestones in its strategy to become a leading psychedelic drug developer and specialty clinics operator. – Developed clear drug development pathway for NEO-001, the industry’s first psilocybin-based obesity treatment with near-term clinical milestones. – Partnered with well-establishedRead More »NeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate Developments

                en_USEnglish